ERBB2 and breast carcinoma: In this study, we found that 71.5% of patients had luminal molecular subtype breast cancer (luminal A, 29.3% and luminal B, 42.2%), compared to 28.5% of non-luminal breast cancer (triple-negative, 22.5% and HER2-enriched, 6.0%).